Literature DB >> 36266281

Viral transduction of primary human lymphoma B cells reveals mechanisms of NOTCH-mediated immune escape.

Maurizio Mangolini1,2, Alba Maiques-Diaz3, Stella Charalampopoulou3, Elena Gerhard-Hartmann4, Johannes Bloehdorn5, Andrew Moore1,2, Giorgia Giachetti1,2, Junyan Lu6,7, Valar Nila Roamio Franklin8, Chandra Sekkar Reddy Chilamakuri8, Ilias Moutsopoulos1, Andreas Rosenwald4, Stephan Stilgenbauer5, Thorsten Zenz9,10, Irina Mohorianu1, Clive D'Santos8, Silvia Deaglio11, Daniel J Hodson1,2, Jose I Martin-Subero3,12, Ingo Ringshausen13,14.   

Abstract

Hotspot mutations in the PEST-domain of NOTCH1 and NOTCH2 are recurrently identified in B cell malignancies. To address how NOTCH-mutations contribute to a dismal prognosis, we have generated isogenic primary human tumor cells from patients with Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL), differing only in their expression of the intracellular domain (ICD) of NOTCH1 or NOTCH2. Our data demonstrate that both NOTCH-paralogs facilitate immune-escape of malignant B cells by up-regulating PD-L1, partly dependent on autocrine interferon-γ signaling. In addition, NOTCH-activation causes silencing of the entire HLA-class II locus via epigenetic regulation of the transcriptional co-activator CIITA. Notably, while NOTCH1 and NOTCH2 govern similar transcriptional programs, disease-specific differences in their expression levels can favor paralog-specific selection. Importantly, NOTCH-ICD also strongly down-regulates the expression of CD19, possibly limiting the effectiveness of immune-therapies. These NOTCH-mediated immune escape mechanisms are associated with the expansion of exhausted CD8+ T cells in vivo.
© 2022. The Author(s).

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 36266281      PMCID: PMC9585083          DOI: 10.1038/s41467-022-33739-2

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   17.694


  74 in total

1.  MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation.

Authors:  A Stacchini; M Aragno; A Vallario; A Alfarano; P Circosta; D Gottardi; A Faldella; G Rege-Cambrin; U Thunberg; K Nilsson; F Caligaris-Cappio
Journal:  Leuk Res       Date:  1999-02       Impact factor: 3.156

2.  Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.

Authors:  Wei Ding; Betsy R LaPlant; Timothy G Call; Sameer A Parikh; Jose F Leis; Rong He; Tait D Shanafelt; Sutapa Sinha; Jennifer Le-Rademacher; Andrew L Feldman; Thomas M Habermann; Thomas E Witzig; Gregory A Wiseman; Yi Lin; Erik Asmus; Grzegorz S Nowakowski; Michael J Conte; Deborah A Bowen; Casey N Aitken; Daniel L Van Dyke; Patricia T Greipp; Xin Liu; Xiaosheng Wu; Henan Zhang; Charla R Secreto; Shulan Tian; Esteban Braggio; Linda E Wellik; Ivana Micallef; David S Viswanatha; Huihuang Yan; Asher A Chanan-Khan; Neil E Kay; Haidong Dong; Stephen M Ansell
Journal:  Blood       Date:  2017-04-19       Impact factor: 22.113

Review 3.  Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions.

Authors:  Xose S Puente; Pedro Jares; Elias Campo
Journal:  Blood       Date:  2018-04-17       Impact factor: 22.113

4.  Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.

Authors:  Alan G Ramsay; Andrew J Clear; Rewas Fatah; John G Gribben
Journal:  Blood       Date:  2012-04-30       Impact factor: 22.113

5.  Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations.

Authors:  John C Riches; Conor J O'Donovan; Sarah J Kingdon; Fabienne McClanahan; Andrew J Clear; Donna S Neuberg; Lillian Werner; Carlo M Croce; Alan G Ramsay; Laura Z Rassenti; Thomas J Kipps; John G Gribben
Journal:  Blood       Date:  2014-05-14       Impact factor: 22.113

6.  Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment.

Authors:  Iris de Weerdt; Tom Hofland; Renate de Boer; Johan A Dobber; Julie Dubois; Denise van Nieuwenhuize; Mehrdad Mobasher; Fransien de Boer; Mels Hoogendoorn; Gerjo A Velders; Marjolein van der Klift; Ester B M Remmerswaal; Frederike J Bemelman; Carsten U Niemann; Sabina Kersting; Mark-David Levin; Eric Eldering; Sanne H Tonino; Arnon P Kater
Journal:  Blood Adv       Date:  2019-09-10

7.  CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment.

Authors:  Piers E M Patten; Andrea G S Buggins; Julie Richards; Andrew Wotherspoon; Jon Salisbury; Ghulam J Mufti; Terry J Hamblin; Stephen Devereux
Journal:  Blood       Date:  2008-03-07       Impact factor: 22.113

8.  Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.

Authors:  Bjoern Chapuy; Chip Stewart; Andrew J Dunford; Jaegil Kim; Atanas Kamburov; Robert A Redd; Mike S Lawrence; Margaretha G M Roemer; Amy J Li; Marita Ziepert; Annette M Staiger; Jeremiah A Wala; Matthew D Ducar; Ignaty Leshchiner; Ester Rheinbay; Amaro Taylor-Weiner; Caroline A Coughlin; Julian M Hess; Chandra S Pedamallu; Dimitri Livitz; Daniel Rosebrock; Mara Rosenberg; Adam A Tracy; Heike Horn; Paul van Hummelen; Andrew L Feldman; Brian K Link; Anne J Novak; James R Cerhan; Thomas M Habermann; Reiner Siebert; Andreas Rosenwald; Aaron R Thorner; Matthew L Meyerson; Todd R Golub; Rameen Beroukhim; Gerald G Wulf; German Ott; Scott J Rodig; Stefano Monti; Donna S Neuberg; Markus Loeffler; Michael Pfreundschuh; Lorenz Trümper; Gad Getz; Margaret A Shipp
Journal:  Nat Med       Date:  2018-04-30       Impact factor: 53.440

9.  Mapping and analysis of chromatin state dynamics in nine human cell types.

Authors:  Jason Ernst; Pouya Kheradpour; Tarjei S Mikkelsen; Noam Shoresh; Lucas D Ward; Charles B Epstein; Xiaolan Zhang; Li Wang; Robbyn Issner; Michael Coyne; Manching Ku; Timothy Durham; Manolis Kellis; Bradley E Bernstein
Journal:  Nature       Date:  2011-03-23       Impact factor: 49.962

10.  A quantitative mass spectrometry-based approach to monitor the dynamics of endogenous chromatin-associated protein complexes.

Authors:  Evangelia K Papachristou; Kamal Kishore; Andrew N Holding; Kate Harvey; Theodoros I Roumeliotis; Chandra Sekhar Reddy Chilamakuri; Soleilmane Omarjee; Kee Ming Chia; Alex Swarbrick; Elgene Lim; Florian Markowetz; Matthew Eldridge; Rasmus Siersbaek; Clive S D'Santos; Jason S Carroll
Journal:  Nat Commun       Date:  2018-06-13       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.